New Therapeutic Target Identified to Prevent Breast Cancer Relapse by Eliminating Dormant Cells

Canadian researchers have uncovered a promising new approach to combat breast cancer recurrence by targeting a specific protein, PIK3C3, vital for the survival of dormant cancer cells. Published in the journal Cancer Research, the study led by Professor Jean-François Côté from the University of Montreal revealed that inhibiting PIK3C3 can eradicate dormant breast cancer cells before they activate and cause metastasis.

Breast cancer remains one of the most common cancers worldwide and is a leading cause of cancer-related death among women in Canada. Despite initial successful treatments, approximately 25% of breast cancer patients face the risk of metastatic recurrence months or even years later. These recurrences happen when cancer cells spread to distant organs and remain in a dormant state, only to reactivate later.

The research focused on understanding how these dormant cells survive during their inactive phase. The team discovered that the protein PIK3C3 is essential for their survival. Targeting this protein disrupts their ability to remain dormant, preventing the initiation of metastasis. This approach could lead to the development of therapeutic strategies that proactively eliminate cells at risk of reactivating, significantly reducing relapse rates.

The study was carried out through collaborations with institutions including McGill University, the University of Toronto, and notable American centers such as the Albert Einstein College of Medicine and the Fred Hutchinson Cancer Center. The findings open new avenues for clinical trials investigating targeted therapies for patients at high risk of metastatic breast cancer.

Oncologist Islam Elkholi from Montreal, the first author of the study, emphasized that pinpointing factors like PIK3C3 that support cell dormancy could revolutionize how breast cancer recurrences are prevented. By focusing on these dormant cells, future treatments could effectively halt the progression of the disease before it manifests clinically.

In summary, this discovery highlights a crucial step forward in tackling the challenge of metastatic relapse in breast cancer, offering hope for more effective and preventative cancer therapies in the near future.